vs

Side-by-side financial comparison of IRIDEX CORP (IRIX) and USCB FINANCIAL HOLDINGS, INC. (USCB). Click either name above to swap in a different company.

USCB FINANCIAL HOLDINGS, INC. is the larger business by last-quarter revenue ($22.2M vs $14.7M, roughly 1.5× IRIDEX CORP). On growth, USCB FINANCIAL HOLDINGS, INC. posted the faster year-over-year revenue change (14.7% vs -69.7%). Over the past eight quarters, USCB FINANCIAL HOLDINGS, INC.'s revenue compounded faster (12.3% CAGR vs 11.9%).

IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.

USCB Financial Holdings, Inc. is a U.S.-headquartered bank holding company that offers comprehensive retail and commercial banking services, including deposit products, personal and business loans, wealth management, and digital banking tools. It primarily serves individual consumers, small and medium-sized enterprises, and local corporate clients across its operating regions in the United States, prioritizing personalized customer experiences and community-oriented financial services.

IRIX vs USCB — Head-to-Head

Bigger by revenue
USCB
USCB
1.5× larger
USCB
$22.2M
$14.7M
IRIX
Growing faster (revenue YoY)
USCB
USCB
+84.5% gap
USCB
14.7%
-69.7%
IRIX
Faster 2-yr revenue CAGR
USCB
USCB
Annualised
USCB
12.3%
11.9%
IRIX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IRIX
IRIX
USCB
USCB
Revenue
$14.7M
$22.2M
Net Profit
$1.4M
Gross Margin
37.2%
Operating Margin
14.7%
Net Margin
6.1%
Revenue YoY
-69.7%
14.7%
Net Profit YoY
-80.3%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRIX
IRIX
USCB
USCB
Q4 25
$14.7M
$22.2M
Q3 25
$12.5M
$25.0M
Q2 25
$13.6M
$24.4M
Q1 25
$11.9M
$22.8M
Q4 24
$12.7M
$23.0M
Q3 24
$11.6M
$21.5M
Q2 24
$12.6M
$20.5M
Q1 24
$11.8M
$17.6M
Net Profit
IRIX
IRIX
USCB
USCB
Q4 25
$1.4M
Q3 25
$-1.6M
$8.9M
Q2 25
$-994.0K
$8.1M
Q1 25
$-1.7M
$7.7M
Q4 24
$-834.0K
$6.9M
Q3 24
$-1.9M
$6.9M
Q2 24
$-2.7M
$6.2M
Q1 24
$-3.5M
$4.6M
Gross Margin
IRIX
IRIX
USCB
USCB
Q4 25
37.2%
Q3 25
32.1%
Q2 25
34.5%
Q1 25
42.5%
Q4 24
44.0%
Q3 24
37.3%
Q2 24
40.7%
Q1 24
37.9%
Operating Margin
IRIX
IRIX
USCB
USCB
Q4 25
14.7%
Q3 25
-11.3%
47.3%
Q2 25
-6.9%
44.0%
Q1 25
-1.7%
44.2%
Q4 24
-3.9%
39.6%
Q3 24
-16.1%
42.5%
Q2 24
-20.9%
39.8%
Q1 24
-28.0%
34.3%
Net Margin
IRIX
IRIX
USCB
USCB
Q4 25
6.1%
Q3 25
-12.6%
35.8%
Q2 25
-7.3%
33.4%
Q1 25
-14.2%
33.5%
Q4 24
-6.6%
30.0%
Q3 24
-16.7%
32.3%
Q2 24
-21.2%
30.3%
Q1 24
-29.5%
26.2%
EPS (diluted)
IRIX
IRIX
USCB
USCB
Q4 25
Q3 25
$-0.09
$0.45
Q2 25
$-0.06
Q1 25
$-0.10
Q4 24
$-0.05
Q3 24
$-0.12
$0.35
Q2 24
$-0.16
Q1 24
$-0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRIX
IRIX
USCB
USCB
Cash + ST InvestmentsLiquidity on hand
$6.0M
$38.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$217.2M
Total Assets
$29.2M
$2.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRIX
IRIX
USCB
USCB
Q4 25
$6.0M
$38.5M
Q3 25
$5.6M
$56.8M
Q2 25
$6.8M
$54.8M
Q1 25
$7.2M
$98.0M
Q4 24
$2.4M
$77.0M
Q3 24
$3.9M
$38.5M
Q2 24
$4.1M
$77.3M
Q1 24
$5.4M
$126.5M
Total Debt
IRIX
IRIX
USCB
USCB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$1.0M
Q3 24
$1.4M
Q2 24
Q1 24
Stockholders' Equity
IRIX
IRIX
USCB
USCB
Q4 25
$217.2M
Q3 25
$4.7M
$209.1M
Q2 25
$6.1M
$231.6M
Q1 25
$852.0K
$225.1M
Q4 24
$2.1M
$215.4M
Q3 24
$2.6M
$213.9M
Q2 24
$4.2M
$201.0M
Q1 24
$6.5M
$195.0M
Total Assets
IRIX
IRIX
USCB
USCB
Q4 25
$29.2M
$2.8B
Q3 25
$28.4M
$2.8B
Q2 25
$31.6M
$2.7B
Q1 25
$34.2M
$2.7B
Q4 24
$29.1M
$2.6B
Q3 24
$30.2M
$2.5B
Q2 24
$31.2M
$2.5B
Q1 24
$34.1M
$2.5B
Debt / Equity
IRIX
IRIX
USCB
USCB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.48×
Q3 24
0.53×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRIX
IRIX
USCB
USCB
Operating Cash FlowLast quarter
$42.8M
Free Cash FlowOCF − Capex
$42.5M
FCF MarginFCF / Revenue
191.4%
Capex IntensityCapex / Revenue
1.4%
Cash ConversionOCF / Net Profit
31.40×
TTM Free Cash FlowTrailing 4 quarters
$95.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRIX
IRIX
USCB
USCB
Q4 25
$42.8M
Q3 25
$-1.2M
$20.1M
Q2 25
$-397.0K
$18.0M
Q1 25
$-1.1M
$14.6M
Q4 24
$-1.2M
$34.8M
Q3 24
$-3.1M
$11.3M
Q2 24
$-1.3M
$18.3M
Q1 24
$-1.6M
$8.1M
Free Cash Flow
IRIX
IRIX
USCB
USCB
Q4 25
$42.5M
Q3 25
$-1.2M
$20.0M
Q2 25
$-410.0K
$18.0M
Q1 25
$-1.2M
$14.6M
Q4 24
$-1.2M
$34.5M
Q3 24
$-3.1M
$11.2M
Q2 24
$18.2M
Q1 24
$-1.7M
$8.0M
FCF Margin
IRIX
IRIX
USCB
USCB
Q4 25
191.4%
Q3 25
-9.4%
80.3%
Q2 25
-3.0%
73.7%
Q1 25
-9.8%
63.9%
Q4 24
-9.8%
150.2%
Q3 24
-26.5%
52.2%
Q2 24
88.8%
Q1 24
-14.0%
45.4%
Capex Intensity
IRIX
IRIX
USCB
USCB
Q4 25
1.4%
Q3 25
0.1%
0.5%
Q2 25
0.1%
0.2%
Q1 25
0.1%
0.2%
Q4 24
0.1%
1.4%
Q3 24
0.0%
0.4%
Q2 24
0.0%
0.4%
Q1 24
0.0%
0.5%
Cash Conversion
IRIX
IRIX
USCB
USCB
Q4 25
31.40×
Q3 25
2.25×
Q2 25
2.22×
Q1 25
1.91×
Q4 24
5.05×
Q3 24
1.63×
Q2 24
2.95×
Q1 24
1.75×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons